Non-insulin therapies are mostly used in type 2 diabetes patients, where body either does not produce enough insulin or is unable to effectively use the insulin it produces. Non-insulin-based medication works with different mechanism of action to reduce blood glucose level and maintain it for optimum glycemic control. For instance, some agents increase the insulin release from pancreatic cells (Sulfonylureas), some agents increase glucose uptake by periphery and reduces hepatic glucose output (Biguanides), some agents slow down digestion of starch in small intestine (alpha glucosidase inhibitors), and some medication reduces post meal sugar by blocking certain enzymes (Incretin mimetics).
Non-Insulin Therapies for Diabetes Market Dynamics
Increasing global incidence and prevalence of diabetes is expected to fuel growth of the non-insulin therapies for diabetes market. Non-insulin therapies are mainly used in type 2 diabetes, which accounts for around 90% of the global diabetes cases. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, worldwide prevalence of diabetic patients was around 425 million, of which around 400 million patients were suffering from type 2 diabetes. As per the World Health Organization (WHO) 2017 report, diabetes is one of the top 3 causes of death among non-communicable diseases worldwide, with 114.4 million cases in China, 72.9 million cases in India, and 30.2 million cases in the U.S.
The global economic burden of diabetes is high and is expected to substantially increase over the forecast period. According to the American Diabetes Association research in March 2018, the total costs of diagnosed diabetes have risen to US$ 327 billion in 2017 from US$ 245 billion in 2012. Therefore, non-insulin therapies for diabetes market is expected to witness growth in the near future.
Moreover, companies are launching new products and combination therapies in the market, which is expected to drive growth of the global non-insulin therapies for diabetes market. For instance, in 2017, the Food and Drug Administration (FDA) approved Novo Nordisk’s Ozempic (semiglutide), which is once a week GLP-1 analog, would increase the patient compliance. In December 2017, FDA approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor called ertugliflozin (Steglatro), which is jointly developed by the Merck & Co. and Pfizer Inc. and in January 2018, the European Medicines Agency (EMA) granted approval for the same in Europe.
However, high cost of newer class of drugs when compared to the conventional drugs are expected to negatively impact the non-insulin therapies for diabetes market growth, especially in regions such as South Asia, where there is large number of patients suffering from type 2 diabetes. For instance, GLP-1 analog costs around US$ 492 for 30 day therapy, whereas Biguanides and sulfonylureas costs around US$ 5-9 for 30 day therapy.
Non-insulin Therapies for Diabetes Market: Regional Insights
On the basis of region, the global non-insulin therapies for diabetes market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to drive growth of the non-insulin therapies for diabetes market due to highest diabetes expenditure in the U.S. According to the International Diabetes Federation (IDF), in 2017, around 17,100 new cases of diabetes were detected in the U.S. Asia Pacific is one of the most lucrative region due to increased diabetes burden in China and India, collectively having over 180 million patients suffering from diabetes. According to the American Diabetes Association (ADA), rising incidence of type 2 diabetes in South Asia is likely to be over 150% between 2000 and 2035.
Non-insulin Therapies for Diabetes Market: Competitive Landscape
Key players operating in the global non-insulin therapies for diabetes market include AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, and Takeda Pharmaceuticals.
Major players are increasingly targeting the newer class of drugs such as GLP-1 analogs or SGLT2. SGLT 2 inhibitors have been approved for use, as a treatment for diabetes since 2013. Most of the drugs under SGL2 inhibitors such as Dapagliflozin, Canagliflozin, and Empagliflozin were launched after 2013. However, intense competition in the market could make it difficult for one particular company to grab larger market share in the non-insulin therapies for diabetes market.
Non-insulin Therapies for Diabetes Market: Taxonomy
On the basis of drug class, the global non-insulin therapies for diabetes market is segmented into:
On the basis of route of administration, the global non-insulin therapies for diabetes market is segmented into:
On the basis of distribution channel, the global non-insulin therapies for diabetes market is segmented into:
On the basis of region, the global non-insulin therapies for diabetes market is segmented into:
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.